wiki pageCreated: 2026-04-02T07:20:08By: crosslink-migrationQuality:
50%✓ SciDEXID: wiki-companies-neuraly
📖 Wiki Page
company549 wordssynced 2026-04-02
Overview
Neuraly, Inc. is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, with a primary focus on Parkinson's disease. The company's lead candidate, NLY01, is a novel glucagon-like peptide-1 receptor (GLP-1R) agonist designed to protect dopaminergic neurons and halt disease progression[@neuraly].
Company Overview
| Attribute | Details | |-----------|---------| | Founded | 2016 | | Headquarters | South Korea (Seoul) / USA | | CEO | Dr. Kwang-Soo Kim | | Sector | Biotechnology | | Focus | Neurodegenerative diseases |
Technology Platform
GLP-1 Receptor Agonism
Neuraly's approach centers on GLP-1 receptor activation in the brain. GLP-1R agonists have shown neuroprotective properties in multiple preclinical models of Parkinson's disease and Alzheimer's disease[@glpr].
Mechanism of Action:
Astrocyte Modulation: NLY01 blocks the conversion of astrocytes to a toxic A1 phenotype induced by activated microglia
Neuroprotection: Prevents neurodegeneration in dopaminergic neurons
Anti-inflammatory: Reduces neuroinflammation through microglial modulation
Differentiation
Unlike antibody-based approaches targeting alpha-synuclein aggregation, NLY01 works through a receptor-mediated mechanism that modulates the brain's immune response and protects neurons from toxic species.
Clinical Pipeline
NLY01 — Parkinson's Disease
...
Overview
Neuraly, Inc. is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, with a primary focus on Parkinson's disease. The company's lead candidate, NLY01, is a novel glucagon-like peptide-1 receptor (GLP-1R) agonist designed to protect dopaminergic neurons and halt disease progression[@neuraly].
Company Overview
| Attribute | Details | |-----------|---------| | Founded | 2016 | | Headquarters | South Korea (Seoul) / USA | | CEO | Dr. Kwang-Soo Kim | | Sector | Biotechnology | | Focus | Neurodegenerative diseases |
Technology Platform
GLP-1 Receptor Agonism
Neuraly's approach centers on GLP-1 receptor activation in the brain. GLP-1R agonists have shown neuroprotective properties in multiple preclinical models of Parkinson's disease and Alzheimer's disease[@glpr].
Mechanism of Action:
Astrocyte Modulation: NLY01 blocks the conversion of astrocytes to a toxic A1 phenotype induced by activated microglia
Neuroprotection: Prevents neurodegeneration in dopaminergic neurons
Anti-inflammatory: Reduces neuroinflammation through microglial modulation
Differentiation
Unlike antibody-based approaches targeting alpha-synuclein aggregation, NLY01 works through a receptor-mediated mechanism that modulates the brain's immune response and protects neurons from toxic species.
A 36-week, randomized, double-blind, placebo-controlled Phase 2 trial evaluated NLY01 in participants with early untreated Parkinson's disease at 58 U.S. movement disorder clinics[@nly].
Trial Results:
NLY01 was safe and well-tolerated
No deaths reported during the study period
Primary endpoint: Change in MDS-UPDRS scores
Secondary endpoints: Motor function, non-motor symptoms
Preclinical Programs
| Program | Target | Indication | Status | |---------|--------|------------|--------| | NLY02 | GLP-1R | Alzheimer's disease | Preclinical | | NLY03 | GLP-1R | ALS | Discovery |
Scientific Rationale
GLP-1 in Neurodegeneration
Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated neuroprotective effects in multiple studies:
Parkinson's Disease Models: GLP-1R activation protects dopaminergic neurons in 6-OHDA and MPTP models[@glpr]
Alzheimer's Disease: Reduces amyloid-beta toxicity and improves cognitive function
Multiple Sclerosis: Modulates neuroinflammation
Astrocyte-Microglia Interaction
NLY01 specifically targets the pathological communication between microglia and astrocytes:
Activated microglia release cytokines that convert astrocytes to A1 phenotype
A1 astrocytes produce toxic factors that kill neurons
NLY01 blocks this conversion, preserving neuronal health